NCT00227422View on ClinicalTrials.gov

Assess the Non-inferiority of GSK Biologicals' Mencevax™ ACWY (Manufactured by a New Process) vs Mencevax™ ACWY (the Already Existing Vaccine in the Market) When Given as a Single Dose to Subjects Aged 2-30 Yrs

PHASE4CompletedINTERVENTIONAL

Enrollment

324

Participants

Timeline

Start Date

June 30, 2005

Study Completion Date

November 30, 2005

Conditions

Infections, Meningococcal

Interventions

BIOLOGICAL

Mencevax ACWY

Trial Locations (1)

1107-2020

GSK Investigational Site, Beirut

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT00227422 - Assess the Non-inferiority of GSK Biologicals' Mencevax™ ACWY (Manufactured by a New Process) vs Mencevax™ ACWY (the Already Existing Vaccine in the Market) When Given as a Single Dose to Subjects Aged 2-30 Yrs | Biotech Hunter | Biotech Hunter